Week Ending June 14, 2021

FDA Approves Two Hepatitis C Treatments for Younger Children
“On June 10, the Food and Drug Administration (FDA) extended its approval of Epclusa (sofosbuvir/velpatasvir) and Mavyret (glecaprevir/pibrentasvir) for the treatment of hepatitis C in children ages 3 and older. Both combination pills are effective against all genotypes of hepatitis C virus (HCV).”

Synthetic overhaul for hepatitis C drug could ease manufacturing demands
“A team at Merck & Co has developed a five-step method for synthesising uprifosbuvir with a 50-fold increase in yield over the previous manufacturing process. The scalable strategy minimises undesirable side products and could be adapted to synthesise a range of nucleosides to help meet global demand for antiviral therapies.”

One Simple Test Prevents This Deadly Cancer
“It’s one of the deadliest cancers and yet, you might not even realize you have it or that you’re at risk… The American Cancer Society estimates that this year, we’ll see more than 42,000 new cases of liver cancer. And about 30,000 folks will die from this extremely deadly form of cancer.”

What to know about hepatitis C and psoriasis
“Psoriasis is an inflammatory condition that causes itchy patches to form on the skin. Hepatitis C is a liver disease that occurs due to the hepatitis C virus. Research is still ongoing, but evidence suggests the two conditions may interact and exacerbate each other’s symptoms.”